OS Therapies Incorporated

Stage 3 · Topping · week 1

As of Oct 22, 2026, OS Therapies is in Stage 3, the topping phase, now in its first week (since Oct 20, 2026). It closed at $1.25, 44.2% below its 52-week high and below its 200-day average, which is falling.

$1.25

+0.00% today

$58.5M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Topping: the uptrend is tiring

Setup score

—

Momentum

Steady

Edge

—

Is OSTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2024-08-01 → 2026-10-22

S? 41w

S1 9w

S4 19w

2024-08-012026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S? 41w → S1 9w → S4 3w → S1 8w → S2 4w → S3 6w → S4 19w → S1 7w → S2 6w → S3 9w → S2 3w → S3 1w current

Total tracked: 116 weeks across 12 stage runs.

OSTX among Biotechnology286th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…286	OSTXOS Therapies Incorporated	Stage 3 · wk 1	33	−24.2%

vs 52W High

-44.2%

$1.16 lo$2.24 hi

44.2% below 52W high, weakening from peak

The stock is rolling over from its 52-week high. In Stage 3 distribution, new long positions carry high risk.

Stage Maturity

Week 1

1w13w26w

Week 1, early distribution

How long this stock has been in Stage 3 distribution. Longer tops often precede deeper Stage 4 declines.

vs 200 DMA

-20.5%

200 DMA: $1.57 · sloping down

Stock is losing its 200 DMA. Once lost, it confirms Stage 4 risk. This is a major red flag for existing holders.

Rel Volume

0.51x

vs 50-day avg

Volume spikes on down days during Stage 3 signal distribution, with institutions exiting. Stage analysis reads that as a warning against new long positions.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-24.2%

-17.8%

-13.8%

YTD

-6.7%

-30.6%

Scan Membership

Not in any current scan.

Recent Stage Timeline

2026-10-22S3

Wk 1 · Vol 0.51x

2026-10-21S3

Wk 1 · Vol 0.47x

2026-10-20S32→3

Wk 1 · Vol 0.48x

2026-10-19S2

Wk 3 · Vol 1.06x

2026-10-16S2

Wk 3 · Vol 0.80x

2026-10-15S2

Wk 3 · Vol 0.57x

2026-10-14S2

Wk 3 · Vol 0.76x

2026-10-13S2

Wk 3 · Vol 1.26x

2026-10-12S2

Wk 2 · Vol 0.38x

2026-10-09S2

Wk 2 · Vol 0.65x

2026-10-08S2

Wk 2 · Vol 1.05x

2026-10-07S2

Wk 2 · Vol 0.94x

Moving averages & range

50 DMA

$1.61

200 DMA

$1.57

52W High

$2.24

52W Low

$1.16

5D Low

$1.25

Resistance levels (recent highs)

20d High

$1.66

60d High

$1.88

120d High

$2.24

250d High

$2.24

Next resistance

+32.8%

to 20d High

Dividend Yield

0.00%

P/B -4.8

OS Therapies: quick answers

What stage is OS Therapies in?

As of Oct 22, 2026, OS Therapies (OSTX) is in Stage 3, the topping phase. It entered Stage 3 on Oct 20, 2026 and is in its first week there. What the four stages mean

Is OS Therapies in an uptrend?

Its uptrend has stalled. OS Therapies is in Stage 3, the topping phase that follows an advance. It trades 20.5% below its 200-day average, which is falling.

How far is OS Therapies from its 52-week high?

OS Therapies closed at $1.25 on Oct 22, 2026, 44.2% below its 52-week high of $2.24. Its 52-week low is $1.16.

How has OS Therapies performed over the past year?

As of Oct 22, 2026, OS Therapies is down 30.6% over the past year and down 6.7% so far in 2026.

Which sector and industry is OS Therapies in?

OS Therapies is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. The company's pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. The company was incorporated in 2018 and is based in Grasonville, Maryland.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.